News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Datavault AI faces shareholder suit over securities law violations
Law firm Robbins LLP is investigating allegations that officers and directors of Datavault AI Inc. breached fiduciary duties and violated securities laws, filing a shareholder alert.
Warner Music acquires Sureel AI for music generation control
Warner Music Group has acquired Sureel AI, a startup focused on AI-generated music rights and attribution. The deal reflects major labels' shift toward owning AI music tools rather than fighting them.
INTERVENT merges 25 years of health coaching with AI chatbots
INTERVENT Health AI combines clinical health coaching data with conversational AI. The startup aims to bring evidence-backed behavior change to enterprise wellness programs.
Pharma Giants Bet $50M on World Cup Ads as FDA Tightens Scrutiny
Sanofi and Amgen partner with US host cities for 2026 World Cup visibility. But drugmakers face heightened regulatory risk as FDA cracks down on misleading pharma commercials.
Roche's colon cancer combo hits FDA priority review with 50% death-risk cut
FDA grants priority review for Tecentriq plus chemotherapy in stage III colon cancer. Phase III data showed 86% disease-free survival at 36 months versus 76% with chemotherapy alone.
Akeso's gumokimab wins China approval for psoriasis with 94.6% clearance at week 12
Akeso's IL-17 inhibitor achieved near-complete skin clearance in Phase III trials and requires only 17 injections yearly. The drug is now approved in China for moderate-to-severe plaque psoriasis.
Indena and Chemi partner on peptide drug conjugates manufacturing
Two European CDMOs are positioning themselves to supply the infrastructure for peptide drug conjugates, a class of targeted cancer therapies gaining traction as alternatives to antibody drug conjugates. Learn what's driving adoption.
Novo's Wegovy pill wins UK approval as Eli Lilly fight intensifies
UK regulator approves oral semaglutide for obesity, but NHS coverage remains unclear. Meanwhile, 55,000 patients queue on private platforms and Novo reports 3M US prescriptions in five months.
Daiichi Sankyo targets top-five oncology by 2035 with $19.1B ADC pipeline
Japanese pharma Daiichi Sankyo plans to invest $18.5B in R&D over five years and expects DXd antibody-drug conjugates to generate $19.1B in peak sales. How it plans to compete beyond Enhertu.
Curia tackles steroid API supply with particle size control
Olivier Roux, Senior Director at Curia, explains how the CDMO simplifies manufacturing of corticosteroids and hormonal therapies—molecules used to treat asthma, autoimmune disease, and diabetes—and prepares for next-generation innovation.
Gorilla Adenovirus Skips Liver, Targets Tumors Naturally
ReiThera's gorilla adenovirus vector avoids pre-existing human immunity and liver sequestration while replicating selectively in cancer cells. The platform carries 36 kilobases of genetic cargo, 8x larger than AAV alternatives.
Three biotech labs bypass antibiotic resistance without creating new resistance
Researchers at three institutions developed three separate approaches to kill antibiotic-resistant bacteria using gold nanoparticles, modified bacteria, and phage therapy. None triggered resistance in sustained treatment—a major departure from conventional antibiotics.